One should be able to harness this endogenous T cell response in humanized mice by efficient vaccine formulations to control successive EBV infection, but this has not been easy so far, in part because we lack efficient vaccine formulations that prime protective CD8+ T cell responses [78]. The gene discussed is CD8A; the disease is Epstein-Barr virus infection.